Organization/Society, year of publication | PES, 2008 [9] | ES, 2011 [11] | FCN, 2012 [15] | French Soc. of Pediatrics, 2012a [13] | Australia - New Zealand, 2013 [22] | Central Europe, 2013 [20] | SAHM, 2013 [21] | AAP, 2014 [23] | Arab Emirates, 2016 [27] | EAP, 2017 [30] |
---|---|---|---|---|---|---|---|---|---|---|
Frequent/low trauma fractures and/or low BMD | X | X | X | X | X | Xb | X | |||
Calcium/phosphate metabolism abnormalities | X | X | ||||||||
Immobilization/disabilities | X | X | X | X | ||||||
Dark skin pigmentation | Xc | Xd | X | X | X | X | X | |||
Reduced sun exposure | X | X | X | X | X | |||||
Athletes (indoor sports) | X | |||||||||
Children institutionalized | X | X | ||||||||
Constant use of sunscreens | X | |||||||||
Obesity | X | Xe | X | X | X | X | ||||
Inadequate diets (e.g. vegan) | X | X | X | |||||||
Elimination diets (e.g. cow/s milk allergy), eating disorders | X | X | X | |||||||
On anticonvulsants | X | X | X | X | X | X | X | X | X | X |
On chronic glucocorticoids | X | X | X | X | X | X | X | |||
On HIV medications | X | X | X | X | X | |||||
On antifungals (e.g. ketoconazole) | X | X | X | X | ||||||
On rifampicin | X | X | ||||||||
Malabsorption syndromes | X | X | X | X | X | X | X | X | X | X |
Chronic kidney disease | X | X | X | X | X | X | X | X | X | |
Nephrotic syndrome | X | |||||||||
Hepatic failure and/or cholestasis | X | X | X | X | X | X | X | X | ||
Granulomatous disorders (e.g. tuberculosis) | X | X | X | X | ||||||
Amenorrhea | X | |||||||||
Cancer (different types) | Xf | X | X | X | ||||||
Hepatitis Cg | X | X | ||||||||
Recurrent acute lower respiratory tract infectionsg | X | X | ||||||||
Atopic dermatitisg | X | X | ||||||||
Atopic Asthmag | X | X | ||||||||
Autoimmune diseasesh | X | Xi | X | |||||||
Cardiovascular diseases (especially hypertension) | X | X | ||||||||
Metabolic syndrome, type 2 diabetes | X |